Currently, there are four FDA-approved drugs for the treatment of ALS, including riluzole (GABA receptor inhibitor), radicava (antioxidant), tofersen (SOD1-ASO), and relyvrio (coformulation of sodium phenylbutyrate and taurursodiol) [9–17]. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.